- Source BioScience invest in digital pathology platform
Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare
Driving down turnaround times (TATs), to enable a more rapid diagnosis and treatment of patients is the key philosophy of Source BioScience.
As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips.
As cancer cases continue to increase amongst a growing and ageing population and a cash constrained NHS face the challenge to sign off on large capital expenditure projects, the introduction of digital pathology at Source BioScience further enhances our partnership with private and government funded hospitals throughout the UK to meet the TATs demanded by governing bodies.
With access to a team of over 60 leading Consultant Pathologists Source BioScience is able to reduce TATs for hospitals to report back to patients such as those waiting on the results of their biopsies to meet the Two Week Wait (TWW) target issued by the NHS governing body. The introduction of digital pathology to our suite of services will further enhance these capabilities.
Operating from an ISO accredited, state of the art laboratory at its headquarters in Nottingham, the ability to provide digitised images of tissue taken from patient biopsies, to over 100 hospitals across the UK and Ireland, will lead to an improved service to NHS hospitals and private healthcare providers in cancer diagnosis and treatment.
Russell Wheatcroft, Commercial Director of Source BioScience, said “We have received a record level of work from NHS Histopathology departments in 2017, and 2018 looks set to surpass records from last year. It is evident that with an ageing population, the lack of resource within the NHS and restricted money to invest in technology, the decision to go digital is a necessity. Our ability to provide a solution to extend the capability of the NHS using the digital platform allows us to drive down our own TAT targets to better service the patient with timely diagnosis and treatment. “
All media enquiries to be directed to:
Russell Wheatcroft, Commercial Director
Source BioScience Limited